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ABSTRACT 
World-wide, human immunodeficiency virus (HIV) transmission most often takes 
place in the genital tract during heterosexual intercourse, but the site where HIV most 
commonly establishes primary infection in the female genital tract remains unknown. 
Several factors including viral load in the HIV-infected individual, presence of genital 
infections, genotype and possibly sex hormone levels influence the risk of HIV 
acquisition. In addition, cationic polypeptides with anti-HIV activity in vitro including 
secretory leukocyte protease inhibitor (SLPI), Elafin/Trappin-2, human neutrophil 
peptide (HNP) 1-3 and LL-37 may play dual roles in vivo with both an antiviral effect 
and target cell-recruiting properties.  
 
For this thesis, we investigated the distribution of potential HIV target cells in three 
anatomical regions (ectocervix, endocervix and endometrium) of the female genital 
tract by immunostaining, computerized image analysis and confocal microscopy. 
Furthermore, innate immune peptides were quantified in genital secretions using 
ELISA and in ectocervical tissue using real-time RT-PCR and immunohistochemistry. 
To characterize antigen presenting cell subsets and their expression of HIV-binding C-
type lectin receptors (CLRs) ectocervical tissue biopsies were collected from HIV-
negative women at low-risk of HIV infection and HIV-negative female sex workers 
considered to be at high-risk of acquiring such infection. Distinct cell populations were 
identified including CD1a+ Langerin+ Langerhans cells (LCs) in the epithelium and 
CD11c+ DC-SIGN+ myeloid dendritic cells (mDCs), CD68+ DC-SIGN+ Mannose 
receptor+ (MR+) mDCs and/or macrophages as well as CD123+ plasmacytoid dendritic 
cells (pDCs) in the submucosa of the ectocervix. The high-risk women had 
significantly higher expression of CLRs than the low-risk subjects. To map the 
distribution of potential cellular targets and receptors binding to HIV in the endocervix 
and endometrium, tissue biopsies were collected from HIV-uninfected low-risk women 
undergoing hysterectomy. LCs were localized mainly in the columnar epithelium, 
whereas CD4+ CCR5+ T cells were present both within and adjacent to the endometrial 
and endocervical epithelium. CD11c+ DC-SIGN+ MR+ and CD68+ DC-SIGN+ MR+ 
mDCs and macrophages were confined to the submucosa of both tissue types but were 
localized in close proximity to the epithelial surface. To assess the expression of SLPI, 
Trappin-2, HNP 1-3 and LL-37, genital fluid samples and ectocervical biopsies were 
collected from HIV-uninfected low-risk woman and HIV-uninfected sex workers (HIV 
high-risk). LL-37 and Trappin-2 levels were significantly lower among low-risk 
women currently using combined oral contraception. Compartmentalization of the 
investigated factors classed HNP 1-3 as the most abundant factor in genital fluids of 
low-risk woman, whereas SLPI had the highest expression in ectocervical tissue. No 
association between tissue expression and soluble levels of the investigated factors was 
seen at the individual level in either HIV low-risk or high-risk women.  
 
In summary, the spatial distribution of potential HIV target cells and innate immune 
factors may play an important role in HIV transmission events. Thus, a better 
understanding of this environment may contribute to designing HIV-inhibiting 
compounds.  
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1 INTRODUCTION 
 
 
1.1 THE HIV/AIDS EPIDEMIC 
 
A report published in June 1981 described five previously healthy gay men that had 
developed Pneumocystis pneumonia, a disease normally associated with severe 
immunosuppression (MS Gottlieb, 1981). The patients also displayed other 
opportunistic infections and symptoms including fever and weight loss. This and other 
medical reports led to the definition of acquired immune deficiency syndrome (AIDS) 
(Gottlieb et al., 1981, Masur et al., 1981). In 1983 a virus was identified as the 
causative agent of AIDS and was later named human immunodeficiency virus (HIV) 
(Barre-Sinoussi et al., 1983). Since the start of the global HIV epidemic in the 1980’s, 
25 million individuals have died due to the infection and it is estimated that more than 
33 million people are living with HIV today (UNAIDS.org, 2010). The epidemic is 
thought to have peaked in 1999, but still 2.6 million individuals were infected during 
2009 (UNAIDS.org, 2010). Since the introduction of effective antiretroviral treatment 
(ART) against HIV during 1995 and 1996 (Richman, 2001), the development of AIDS 
can be thwarted, but there exist no definitive cure or vaccine against HIV infection. 
Furthermore, ART only reaches approximately one third of all people in need of it 
(UNAIDS.org, 2010).  
 
HIV can be spread by sexual contact, as blood-borne infection (contaminated blood 
product or shared needles) or from an infected mother to her child (during pregnancy or 
breastfeeding), but the major transmission route varies between different regions in the 
world. In Sub-Saharan Africa, the epicenter of the HIV epidemic (Haase, 2010), HIV 
infection is primarily transmitted via unprotected sexual intercourse and mother to child 
transmission (UNAIDS.org, 2010). In this region, 68% (22.5 million) of all HIV 
infected individuals live and the proportion of infected women is higher. Among young 
people aged 15-24 years women are as much as eight times more likely than men to be 
HIV-positive. In contrast, intravenous drug users (IVDU) and sex workers are the main 
affected in the epidemics of Eastern Europe and Central Asia (UNAIDS.org, 2010).  
 
In Sweden, the incidence of new HIV infections has increased slowly over the last ten 
years and today 5300 individuals are living with HIV (www.smittskyddsinstitutet.se, 
2011). The major group of newly infected represents individuals infected 
heterosexually before arrival to Sweden followed by men who have sex with men 
(MSM) infected within Sweden.   
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1.2 THE HUMAN IMMUNODEFICIENCY VIRUS 
 
 
1.2.1 Origin of HIV 
 
The most common explanation for the origin of HIV is the transfer of Simian 
Immunodeficiency virus (SIV) from African monkeys to humans as early as 100 years 
ago (Levy, 2007). There are two separate types of HIV; HIV-1 and HIV-2, which 
differs in their phylogenetic (evolutionary) relationship with other primate lentiviruses. 
HIV-1 is believed to stem from SIV from chimpanzees (SIVcpz) (Hahn et al., 2000) 
and HIV-2 to originate from another primate species in Africa, the sooty mangabeys 
(SIVsmm) (Silvestri et al., 2007). Despite the name of the virus, SIV infection in their 
natural hosts (i.e. chimpanzees and soothy mangabeys) does not cause clinical disease. 
In contrast, SIV infection in a non-natural host, for example in the rhesus macaque 
monkeys of Asian origin, causes an illness similar to AIDS (simian AIDS). This animal 
model of AIDS is now widely used for HIV research purposes for the study of various 
aspects of the infection. The different disease outcome in natural and non-natural SIV 
host may partly be explained by the lower levels of immune activation seen in the 
natural hosts (Silvestri et al., 2007). The earliest documented evidence of HIV-1 
infection in humans came from an African seropositive sample collected in 1959 in 
Congo (Zhu et al., 1998), but the epidemic started spreading over the world during the 
1980ies. Several factors have been proposed for this delay, including urbanization, 
deforestation, increased international travelling, prostitution and most likely the use of 
needle injecting devices (Levy, 2007).  
 
Both HIV-1 and HIV-2 are subclassified into groups, based on phylogenetic criteria. 
HIV-1, the virus responsible for the global HIV epidemic, consists of group M (main), 
O (outlier) and N (non M, non O) (Levy, 2007). The predominant M group is further 
divided into 11 subtypes (or clades) that are differently distributed geographically. 
Furthermore, recombinant viruses often emerge in populations where multiple clades 
cocirculate and these so called circulating recombinant forms (CRF) represent over 
20% of all new infections (Hemelaar et al., 2011). HIV-2 infection is most prevalent in 
West African nations, but is also reported in countries with historical and 
socioeconomic ties with this region. Compared with HIV-1, HIV-2 is considered to be 
less infectious and the progression to AIDS is slower in HIV-2 infected individuals 
(Campbell-Yesufu and Gandhi, 2011). 
 
 
 
1.2.2 Viral structure 
 
HIV is a member of the genus Lentivirus in the Retrovirus family. The HIV (onwards 
HIV-1 is referred to as HIV) particle is 100 nm in diameter, which is around 60 times 
smaller than a red blood cell. The viral genome contains 9 genes (encoding 15 
proteins): the structural Env, Gag and Pol, the regulatory Rev and Tat and the accessory 
Vif, Vpu, Nef and Vpr. The viral envelope is of host origin, but in addition to host 
   3 
cellular protein also the virally derived proteins (envelope glycoproteins) gp41 
(transmembrane protein) and gp120 (outer surface protein) are embedded in the lipid 
bilayer (Sierra et al., 2005). The coneshaped core is composed of the gag p24 capsid 
protein. Inside the capsid are two identical copies of singe stranded RNA molecules, 
the enzymes reverse transcriptase (RT), viral protease, integrase and Vif, Vpu, Nef and 
Vpr. By RT the viral RNA is reverse transcribed into DNA, which subsequently is 
incorporated into the host cell DNA by the viral integrase. The RT enzyme is very error 
prone and it has been estimated that up to 10 base changes in the HIV genome can 
occur per replicative cycle (Levy, 2007). This in combination with high rates of viral 
replication is basis for the vast genetic variability seen for HIV which in turn enables 
the virus to evade the immune system and develop resistance to pharmacological 
treatments.  
 
HIV infection of target cells requires fusion of the viral membrane and cell membrane 
by sequential interaction of the viral gp120 firstly with cell surface CD4 and secondly 
with one of two co-receptors, chemokine (CC) receptor molecules CXCR4 or CCR5. 
Based on co-receptor usage the HIV variants are divided into R5 (using CCR5), X4 
(using CXCR4) or R5X4 (can use both) strains (Berger et al., 1998). Both R5 and X4 
HIV are present in body fluids including semen, blood, cervicovaginal and rectal 
secretions, however R5 HIV is responsible for primary transmission events and 
dominate the early stages of HIV disease (Grivel et al., 2011). The mechanisms behind 
this selection of R5 HIV in initial transmission and infection are not entirely understood 
but may be partly explained by reduced glycosylation of HIV envelope protein 
(Derdeyn et al., 2004, Liu et al., 2008). This will be discussed more in the CLR section 
of this thesis. X4 viruses may evolve at later stages of the HIV infection and this is 
associated with a more rapid loss of CD4+ T cells and accelerated progression to AIDS 
(Connor et al., 1997). Of note, also other receptors and molecules including, 
complement receptors (CRs) (Doepper et al., 2002), Fc receptors (FcRs)(Willey and 
Aasa-Chapman, 2008), Syndecan-3 (de Witte et al., 2007a) and C-type lectin receptors 
(CLRs) (Turville et al., 2002) have the capacity of HIV binding, as will be described 
later. 
 
 
 
1.2.3 Natural course of HIV infection 
 
HIV is primarily a mucosal infection and transmission most often takes place in the 
genital tract during heterosexual intercourse. Based on non-human primate studies of 
mucosal SIV-infection, it is believed that the virus initially establish a small founder 
population of infected cells in the submucosa which undergoes local expansion during 
the first week of infection. This expansion generates virus and infected cells which 
subsequently disseminate and establish infection in secondary lymphoid organs and 
then spreads through the blood stream. During the second week of infection a systemic 
infection is established with the virus replicating rapidly in the lymphoid organs 
(Haase, 2010).  This is the basis behind the suggestion for prevention strategies during 
the first week of infection, which could target either the small founder population or the 
local expansion, before systemic infection is established.  
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Figure 1 illustrates the three phases of HIV infection; the acute or primary phase, the 
chronic phase and AIDS. Summarized, viral RNA can be detected around a week after 
infection and usually peak near the end of the second week.  Primary infection with 
HIV (PHI) can be associated with clinical symptoms which are usually seen within 2-4 
weeks following infection (Lindback et al., 2000). Usually over 50% of infected 
individuals exhibit clinical symptoms including malaise, swollen lymph glands, sore 
throat and fever (Tindall et al., 1988, Cooper et al., 1985). During the acute phase of 
HIV infection the number of CD4+ T cells declines throughout the body. In the 
gastrointestinal tract, which harbors the majority of total body T lymphocytes, a marked 
depletion of memory CD4+ T cells is seen during acute infection (Brenchley et al., 
2004, Mattapallil et al., 2005). Moreover, the CD4+ T cells in the gastrointestinal tract 
may not be restored following the initiation of antiretroviral treatment (Guadalupe et 
al., 2006). This loss of CD4+ T cells, the main target cell for the virus, in combination 
with the appearance of HIV-specific CD8+ cytotoxic T lymphocytes (CTLs) and 
possibly HIV-specific CD4+ T cells and HIV neutralizing antibodies, are thought to be 
responsible for the decline in viral load to a viral set point (McMichael and Rowland-
Jones, 2001, Mascola, 2003). During the chronic stage a steady state of viral production 
is present and a gradual loss of CD4+ T cells take place. Without antiretroviral 
treatment, the time from infection to AIDS development is approximately 8 years.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  
Schematic illustration of the natural course of a typical HIV-1 infection showing viral load (red line), 
CD4+ T cell counts (purple dotted line), CTL reponse (black line) and Ab response (grey line). 
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1.3 THE FEMALE GENITAL TRACT 
 
 
The female genital tract (FGT) consists of the ovaries, the fallopian tubes, the uterus, 
the cervix uteri and the vagina (Figure 2). The vagina and ectocervix are constantly 
exposed to the external environment and are rich in resident microbial flora, which in a 
healthy vaginal mucosa is dominated by lactobacilli strains. The flora contributes in 
lowering the vaginal pH which in turn protects against foreign pathogens (Kaushic, 
2011). In comparison, the upper parts of the FGT (i.e. ovaries, fallopian tubes, uterus 
and endocervix) are less exposed to the external environment (Wira and Fahey, 2008). 
 
The mucosa of the uterus is called the endometrium and it is covered with a single layer 
columnar epithelium (a, figure 2). The endometrium is divided into the functional 
(superficial) layer and the basal layer. The functional layer varies with the changes in 
sex hormones during the menstrual cycle and is shed during the menstrual bleeding. 
Below the endometrium is a layer of smooth muscle called the myometrium (Kurman, 
2002). The cervix uteri is the part of the uterus that protrudes into the vagina. It is 
further divided into the outside portion called the ectocervix and the inside portion 
called the endocervix. The ectocervix (and the vagina) are lined with a non-keratinized 
multi-layered squamous epithelium (c, figure 2), whereas the endocerix is covered with 
a single layer mucin-secreting columnar epithelium (a, figure 2). The epithelium of the 
endocervix is richly folded to increase the surface area and these cleft-like infoldings 
give an impression of glands. Moreover, the columnar epithelium may protrude outside 
the cervical canal (onto the ectocervix), so called cervical ectopy (Jacobson et al., 
2000). This condition is a result of hormonal influence and is mostly seen in teens, 
during pregnancy and in women using hormonal contraception. The columnar 
epithelium in the ectopy will gradually be replaced by squamous epithelium through a 
process known as metaplasia, which will take place in the transformation zone (TZ) (b, 
figure 2) (Jacobson et al., 2000).  
 
 
 
1.3.1 Cervicovaginal fluid 
 
The epithelial cells of the FGT produce a hydrophilic surface layer called the 
glycocalyx and thick hydrophobic mucus layer (Kaushic et al., 2010). Together with 
secretions from the cervical vestibular glands, plasma transudate and endometrial and 
oviductal fluids (Elstein, 1978, Huggins and Preti, 1981) they compose the 
cervicovaginal genital fluids. The character of the mucus from the cervical vestibular 
glands varies during the menstrual cycle between a transport medium for spermatozoa 
at time of ovulation to a barrier for fertilization at other times (Khaldoun Sharif, 2006).  
Although more penetrable at time of ovulation, the cervical mucus is never totally 
impenetrable. This has been shown experimentally by using radiolabeled microspheres 
which entered the uterus within minutes following intravaginal application both during 
the proliferative and secretory menstrual cycle phase. However, entry to the fallopian 
tubes was only observed during the proliferative phase (Zervomanolakis et al., 2007, 
Kunz et al., 1996). The mucus itself physically protect against invading pathogens 
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including HIV (Kaushic et al., 2010, Maher et al., 2005). In addition, the genital 
secretions contain cationic polypeptides with antimicrobial activity. These polypeptides 
are produced by epithelial cells and various immune cells throughout the genital tract 
and will be discussed more thoroughly later in this thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 
The female genital tract. (I) Ovaries, (II) the fallopian tubes, (III) the uterus, (IV) the cervix uteri and 
(V) the vagina. (a)The uterus and endocervix are lined with a single layer columnar epithelium, whereas 
(c) the ectocervix and vagina are covered with a multilayered squamous epithelium. (b)Transformation 
zone. Copyright of Sam Hirbod, illustrator.  
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1.4 THE MUCOSAL IMMUNE SYSTEM 
 
 
The mucosal immune system in the female genital tract is uniquely adapted to the 
highly specialized functions of reproduction, whilst concurrently protecting against 
foreign pathogens. The human immune system consists of immune cells and soluble 
molecules such as cytokines, chemokines, proteins of the complement system, cationic 
polypeptides and antibodies. The immune system can be divided into the innate and 
adaptive arms of which the innate is believed to have developed prior to the adaptive 
(Janeway, 2005). The innate immune system represents the first line of defense against 
pathogens and provides the necessary alert signal for the adaptive immune system to 
the fact that an infectious pathogen has attacked the body. The innate immune system 
recognize non-self pathogens by their pathogen-associated molecular patterns (PAMPs) 
through pattern recognitions receptors (PRRs) such as Toll-like receptors (TLRs) and 
C-type lectin receptors (CLRs) (Geijtenbeek and Gringhuis, 2009). The innate response 
is rapid, whereas the adaptive response takes longer time to develop (Janeway, 2005). 
This is because adaptive immunity generates and clonally expands cells with specificity 
of foreign epitopes. Some of these cells are long-lived and provide immunological 
memory. Considering all components and the complexity of the immune system, all 
aspects will not be discussed here. Rather, the aspects relevant to this thesis will be 
introduced.  
 
 
 
1.4.1 Dendritic cells 
 
DCs consist of a heterogeneous cell population found in blood, lymphoid tissue and 
various tissues including the FGT mucosa. DCs can be of both myeloid (myeloid DCs, 
mDCs) and lymphoid lineage (plasmacytoid DCs, pDCs) (Donaghy et al., 2006, 
Robinson et al., 1999). Of the two, mDCs are more frequent than pDCs (Larsson, 
2005). Mucosal mDCs express CD11c, an α integrin subunit which together with a β 
integrin subunit (CD18) form the complement receptor 4 (Bilsland et al., 1994). The 
mDCs are further subdivided into Langerhans cells (LCs), generally found within the 
epithelium, and interstitial mDCs localized in the submucosa. The pDCs are found in 
blood and lymphoid organs (Siegal et al., 1999, Grouard et al., 1997) as well as in other 
tissues (Donaghy et al., 2009, Jahnsen et al., 2000, Wollenberg et al., 2002) including 
the FGT mucosa (Papers I-III). The pDCs express CD123 (interleukin-3 receptor) and 
the C-type lectin BDCA-2 (Dzionek et al., 2001).  
 
Three stages of maturation exist for DCs; precursors, immature and mature, and their 
localization and function in the body are dependent on the state of maturation (Turville 
et al., 2003). Immature DCs are distributed in the tissue where they act as sentinels and 
survey the surroundings for evidence of pathogens. Immature DCs are experts on 
antigen uptake and express an array of receptors on their surface for this purpose, 
including different C-type lectin receptors (CLRs), CRs and FcRs. The DCs are capable 
of antigen uptake either via receptor mediated endocytosis or through the receptor-
independent pathway of macropinocytosis (Janeway, 2005). During endocytosis, the 
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DC engulfs the pathogen, whereas whole droplets of fluid are captured during 
micropinocytosis.  DCs mature in response to both endogenous and exogenous stimuli  
and migrate to lymphoid organs (Donaghy et al., 2006). Mature DCs are highly 
efficient at antigen presentation and activation of T cells. During the maturation process 
the phenotype of the DC changes and molecules important for antigen presentation 
such as MHC class II, co-stimulatory and adhesion molecules are up-regulated, 
whereas others, including CLRs and CCR5, are down-regulated.  
 
The pDCs are functionally distinct from mDCs. The pDCs are the professional type 1 
interferon producing cells but are also capable of antigen presentation (Siegal et al., 
1999). The pDCs produce IFN-α in response to viruses, including HIV(Fonteneau et 
al., 2004). 
 
 
 
1.4.2 The role of DCs in HIV infection 
 
DCs have been proposed to play a number of roles in HIV pathogenesis, including 
infection in the genital mucosa, transport of virus to lymphoid tissue and transmission 
of virus to T lymphocytes (Donaghy et al., 2006). All DC subtypes express CD4 and 
the co-receptors CCR5 and CXCR4 to varying degrees (Larsson, 2005), in addition to 
other receptors capable of interaction with HIV.  
 
1.4.2.1  HIV infection of mucosal DCs 
 
Both intraepithelial LCs and submucosal mDCs have been proposed as targets for HIV.  
In the rhesus macaque animal model, SIV+ LCs were detected after vaginal exposure of 
SIV (Hu et al., 2000). In humans, vaginal LCs internalized HIV into cytoplasmic 
organelles but were not productively infected (Hladik et al., 2007), whereas infection of 
skin LCs has been observed (Kawamura et al., 2000). Mucosal LCs may play a 
protective role against sexual HIV acquisition as suggested by a study by de Witte et al, 
where it was shown that HIV uptake via the CLR Langerin in immature skin LCs 
directed the virus to the organelle Birbeck granules, where the virus was degraded (de 
Witte et al., 2007b). However, under inflammatory conditions (de Jong et al., 2008), at 
high viral concentrations, or in the presence of anti-Langerin antibodies the LCs could 
be infected. This suggests that certain conditions may be required for the protective 
function of LCs. Interstitial DCs in the submucosa express other CLRs capable of HIV 
binding, which will be discussed later in this thesis. Submucosal DCs mediated viral 
transmission to T cells in human skin explants (Reece et al., 1998) and infected DCs 
were observed following vaginal exposure of SIV in rhesus macaques (Spira et al., 
1996).   
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1.4.2.2 Trans and cis transmission to T cells  
 
CLR mediated binding of HIV to DCs may result in either trans or cis transmission to T 
cells. The CLRs for which this has been described are DC-specific intercellular 
adhesion molecule-3 grabbing non-integrin (DC-SIGN) (Geijtenbeek et al., 2000, 
Burleigh et al., 2006) and DC-immunoreceptor (DCIR) (Lambert et al., 2008). The DC 
is not infected by HIV during trans transmission, but captures and carries the virus with 
a CLR and mediates local transfer of virus to T lymphocytes (Turville et al., 2003). In 
contrast, the DC is productively infected during cis transmission and newly synthesized 
virions are subsequently transferred to T cells. In cis transmission, the initial capture of 
HIV via a CLR facilitates entry of HIV into the cytoplasm by the conventional 
CD4/CCR5 fusion pathway (Cunningham et al., 2008). Of the two, trans transmission 
is believed to be the first to occur, since the novo production of virus is seen 
approximately 24 h after HIV binding.  
 
1.4.2.3 Other aspects of HIV and DC interaction 
 
Several DC subsets can be HIV infected in vitro, but the level of productive infection in 
DCs is much lower as compared to T lymphocytes (Larsson, 2005). Immature DCs are 
more susceptible to productive HIV infection as compared to mature DCs, which may 
be due to the expression level of CD4 and the co-receptors, intrinsic antiviral properties 
of the DC as well as metabolic activity. HIV infection and replication is enhanced when 
DCs are clustered with CD4+ T cells (Pope et al., 1994) by the formation of an 
infectious synapse between the cells which results in very efficient viral spread 
(McDonald et al., 2003). In the infectious synapse, mature DCs are more efficient of 
viral transfer to T cells than immature DCs. Furthermore, immature and mature DCs 
differ with regard to viral storage. Immature DCs store HIV in small vesicles 
containing few virions, whereas mature DCs have a single or a few large vesicles with 
high quantity of virions (Frank et al., 2002). HIV infection induces alterations in DC 
function. During acute HIV infection the number of DCs in lymphoid tissue increases, 
but their expression of the co-stimulatory molecules CD80 and CD86 are reduced (Lore 
et al., 2002). DC maturation is impaired and HIV-infected DCs express less MHC I and 
CD4 and secrete the immunosuppressive cytokine IL-10 (Larsson, 2005). In 
combination, these alterations may impair the DC ability to activate T cells.  
 
 
 
1.4.3 Macrophages 
 
Macrophages are widely distributed in the tissues of the body, where their main 
function is phagocytosis of pathogens and subsequent destruction in intracellular 
vesicles. Macrophages also have the capacity of antigen presentation to T cells. 
Macrophages express the conventional receptors for HIV binding and fusion (CD4, 
CCR5 and CXCR4) as well as CLRs, CRs and FcRs.  For example, Mannose Receptor 
(MR), a CLR expressed on both macrophages and DCs, has been found to bind and 
mediate transfer of HIV to T lymphocytes (Nguyen and Hildreth, 2003). However, MR 
interaction with HIV did not lead to a productive infection of the macrophage; rather 
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the viral uptake was by phagocytosis (Trujillo et al., 2007). It is suggested that this 
noninfectious route of entry may contribute to CTL activation.  
 
 
 
1.4.4 C-type lectin receptors (CLRs) 
 
The CLRs are predominantly expressed by antigen presenting cells (APCs), such as 
macrophages and DCs, and recognize carbohydrates in a calcium-dependent manner 
via their carbohydrate recognition domain (CRD). The transmembrane CLRs are 
separated into type I and II; type I have several CRDs, whereas type II have a single 
CRD (Gijzen et al., 2006). In addition to mediating endocytic activity after recognizing 
glycosylated ligands on pathogens, the CLRs mediate cell-cell adhesion and clearance 
of apoptotic cells when binding to endogenous carbohydrates (Gijzen et al., 2006). HIV 
cloaks its envelope protein in N-linked glycans to reduce antibody recognition (Doores 
et al., 2010) and all the CLRs with HIV binding capacity bind to these high mannose 
structures on gp120. Four CLRs have been reported to bind HIV: MR (Larkin et al., 
1989, Turville et al., 2001), DC-SIGN (Geijtenbeek et al., 2000), DCIR (Lambert et al., 
2008) and Langerin (Turville et al., 2002). However, as described for Langerin and 
DC-SIGN, the consequences of HIV uptake via CLRs may differ between different 
CLRs. Furthermore, Langerin polymorphisms exist which result in different 
carbohydrate-binding capacities, whereas the DC-SIGN gene is highly conserved 
(Ward et al., 2006). The CLRs are expressed by different APC subtypes; Langerin is 
exclusively expressed by Langerhans cells (Valladeau et al., 2000), whereas DC-SIGN 
and MR are expressed by interstitial DCs and macrophages in the submucosa (de Witte 
et al., 2008, Geijtenbeek et al., 2000, Kamada et al., 2008). DCIR is expressed by APC, 
but its expression on mucosal DC subsets in vivo remains to be established (Lambert et 
al., 2008). The CLR BDCA-2 is expressed by pDCs, but has not been associated with 
binding affinity to HIV. BDCA-2 is involved in endocytic antigen uptake and 
subsequent presentation to T cells, but may also suppress induction of interferon α/β 
production (Dzionek et al., 2001).  
 
As mentioned previously, the majority of HIV variants establishing primary infection 
are R5 strains, independently of the route of transmission. Furthermore, it has been 
observed that the transmitted R5 virus often has reduced gp120 glycosylation (Derdeyn 
et al., 2004, Liu et al., 2008). This would hypothetically make the virus less susceptible 
to recognition by CLRs, but more sensible to neutralizing antibodies. However, 
avoidance of DC stimulation through CLR binding may be more important to the 
establishment of primary infection than the capacity of avoiding neutralizing antibodies 
in a population never previously exposed to HIV. Another theory involves the alpha-4 
beta-7 (α4β7) gut homing integrin, which is expressed on highly susceptible CD4+ T 
cells in the mucosa (Cicala et al., 2009). It is suggested that the α4β7 integrin binds 
more efficiently to viruses with reduced glycosylation (Grivel et al., 2011).   
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1.4.5 Toll-like receptors (TLRs) 
 
TLRs were the first Pattern recognition receptors (PRRs) to be identified. A total of ten 
TLRs have been described in humans and each recognizes distinct PAMPs from 
viruses, bacteria, fungi and parasites. The TLRs are associated with intracellular 
vesicles or expressed on the cell surface of innate immune cells including DCs and 
macrophages (Kawai and Akira, 2011). Also FGT epithelial cells express TLRs 
(Kaushic et al., 2010). PAMP recognition by TLR induces the secretion of 
inflammatory cytokines, type I interferons, chemokines and antimicrobial peptides, 
often mediated by the activation of the transcription factor NF-κB (Kawai and Akira, 
2011). These responses in turn recruit neutrophils and activate macrophages. Moreover, 
TLR signaling leads to DC maturation with up-regulation of co-stimulatory molecules 
necessary for activation of the adaptive immune response (Janeway, 2005).  
 
 
 
1.4.6 Cationic polypeptides with antimicrobial activity 
 
Cationic polypeptides are present in genital secretions and in genital tissue, where they 
constitute part of the innate host defense of the mucosa. These peptides exist both in 
plants and animals, indicating both the importance and senescence of this part of the 
innate immunity. The complete repertoire of cationic polypeptides in FGT secretions is 
unknown, but by using a proteomic approach 20 different peptides were found in 
vaginal fluid (Venkataraman et al., 2005). The peptides differ with regard to cellular 
source and how they exert their antimicrobial activity, but also have common properties 
including amphipathicity (spatial separation of hydrophilic and hydrophobic residues) 
and cationicity (a net positive charge at physiological pH) (Cole and Cole, 2008), 
which are important to mediate peptide insertion into anionic microbial membranes and 
prevent membrane-membrane interactions.  
 
Several of these peptides have anti-HIV activity in vitro, but their role in mucosal HIV 
susceptibility in vivo is more complex. Since they also exert chemotactic and 
immunomodulatory effects on immune cells, they may in fact increase HIV 
susceptibility (Borrow et al., 2010). Whether the pro-or anti-HIV activity predominates 
may be dependent on the cellular origin of the innate factors as well as their distribution 
in the tissue or in the genital secretions (Broliden, 2010). Furthermore, several factors 
influence the levels of the cationic polypeptides, including hormonal changes during 
the menstrual cycle (Wira et al., 2011), inflammatory conditions (Wiesenfeld et al., 
2002, Valore et al., 2006) and genetic polymorphisms (Linzmeier and Ganz, 2005, 
Chowdhury et al., 2006).  
 
1.4.6.1 Defensins 
 
In mammals, defensins are classified into three subfamilies, the alpha-, beta- and theta-
defensins (α-, β- and θ-defensins) (Cole, 2006). All classes of defensins exhibit 
antimicrobial activity against several bacteria, fungi and viruses including HIV in vitro. 
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However, the mature form of θ-defensins is not produced in humans, due to a 
premature termination codon which inhibits its complete translation.  
 
The majority of the α-defensins, human neutrophil peptides (HNP) 1-3, is synthesized 
by neutrophil precursor cells in the bone marrow and stored in primary granules of 
neutrophils in their mature form. However, also other immune cells including NK cells 
and macrophages may produce α-defensins (Klotman and Chang, 2006). The level of 
HNP 1-3 expression is correlated to gene copy numbers, which can range from 5 to 14 
copies per genome between individuals (Linzmeier and Ganz, 2005). HNP 1-3 may 
recruit potential HIV target cells since it has chemotactic effect on T cells, monocytes 
and DCs (Territo et al., 1989, Yang et al., 2000), but also display anti-HIV activity by a 
direct effect on the virion or by inhibiting HIV at the steps of nuclear import and 
transcription in the target cells (Chang et al., 2005). The complexity of the antiviral 
effects of cationic peptides in vivo is illustrated by a prospective study of HIV-exposed 
uninfected female sex workers (Levinson et al., 2009).  Here, a significant association 
was found between HIV neutralizing capacity and elevated levels of HNP 1-3 and the 
cathelicidin LL-37 in genital secretions. However, genital infections (Chlamydia 
Trachomatis and Neisseria  Gonorrea) as well as HIV acquisition also correlated 
significantly with higher levels of HNP 1-3 and LL-37. It may be speculated that the 
antiviral activity of HNP 1-3 and LL-37 was overwhelmed by their chemoattracting 
activities and/or excessive HIV exposure in this case. 
 
1.4.6.2 Cathelicidins 
 
LL-37 is the only member of cathelicidins in humans. It is formed after proteolytic 
cleavage of the precursor hCAP-18, and is found in specific granules of neutrophils and 
in epithelial cells at various mucosal sites including the female genital tract (Frohm 
Nilsson et al., 1999). In the FGT, the cleavage of hCAP-18 into ALL-38 (a peptide with 
similar anti-bacterial activity as LL-37) is mediated by the seminal protease gastricsin. 
This process is pH dependent, since gastricsin is functionally active in the low pH 
milieu of vaginal fluid but inactive at neutral or basic pH (Sorensen et al., 2003). LL-37 
has a broad spectrum of antimicrobial activity including anti-HIV activity in vitro 
(Bergman et al., 2007). The HIV inhibitory activity is believed to be through an effect 
on the targets cells. Furthermore, LL-37 exerts chemotactic activity on T cells, 
monocytes and neutrophils (De et al., 2000, Agerberth et al., 2000) and induces the 
expression and extracellular release of HNP 1-3 from neutrophils (Zheng et al., 2007).  
 
1.4.6.3 Secretory leukocyte protease inhibitor and Elafin 
 
Other peptides with anti-HIV activity in vitro are the serine protease inhibitors; 
secretory leukocyte protease inhibitor (SLPI) and Elafin. They are members of the 
whey acidic protein family and share 40% homology. However, the gene encoding for 
Elafin is highly polymorphic, whereas the SLPI gene is stable (Chowdhury et al., 
2006). SLPI and Elafin are produced by epithelial cells at various mucosal surfaces as 
well as by neutrophils and macrophages (Pfundt et al., 1996, King et al., 2003a). Elafin 
is the mature peptide formed after cleavage of the precursor Trappin-2. However, as no 
specific Elafin antibody exists, Trappin-2 and Elafin are often measured simultaneously 
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in laboratory settings. Furthermore, in many cases Trappin-2 displays similar capacity 
of antimicrobial activity and protection against proteolysis as Elafin (Moreau et al., 
2008, Bourbonnais et al., 2000).  
 
A major function of SLPI, Trappin-2 and Elafin is to protect against excessive 
proteolysis following neutrophil activation (Moreau et al., 2008). Moreover, SLPI, 
Elafin and Trappin-2 display anti-inflammatory activity for example via prevention of 
NF-κB activation and suppression of LPS-induced production of cytokines (Moreau et 
al., 2008). In addition, they have broad spectrum anti-microbial activity and have been 
shown to inhibit HIV in vitro (Kazmi et al., 2006, McNeely et al., 1995, Ghosh et al., 
2010). The anti-HIV activity of SLPI is mediated through binding of a co-factor 
(annexin II) important for stabilization of viral fusion (Ma et al., 2004), whereas Elafin 
is believed to interact directly with the virion (Ghosh et al., 2010). Furthermore, 
elevated levels of Elafin and Trappin-2, but not SLPI, have been associated with 
protection against mucosal HIV acquisition in an epidemiological study (Iqbal et al., 
2009).  
 
 14 
1.5 HIV TRANSMISSION FOLLOWING SEXUAL INTERCOURSE 
 
 
World-wide, HIV transmission most often takes place in the genital tract during 
heterosexual intercourse, but HIV can also be transmitted via rectal and oral 
intercourse. Of the three, receptive anal intercourse carries the highest probability of 
infection (approximately 1:20-1:300) (Hladik and McElrath, 2008), which is attributed 
to the fragile single layer columnar epithelium and abundance of HIV target cells at this 
site. In comparison, the transmission probability for each sexual encounter following 
vaginal intercourse is estimated to 1:200-1:2000 (male-to female) and the lowest risk is 
attributed to the oral route (1:2500).  
 
 
 
1.5.1 HIV infection in the female genital tract 
 
Women appear to be more vulnerable to HIV infection following heterosexual 
intercourse, and this may be attributed to biological as well as social, economic and 
behavioral factors (Kaushic, 2009). Based on animal models (Kaizu et al., 2006, Salle 
et al., 2010), ex vivo human cervical explant studies (Gupta et al., 2002) and genetic 
sequencing (Zhu et al., 1996), it is proposed that both free virions and cell associated 
virus can establish mucosal HIV infection. Furthermore, sequence analysis of virus in 
acute infection show that in the vast majority of sexually acquired HIV infections in the 
FGT, the infection is initiated by a single transmitted founder virus (Keele and 
Derdeyn, 2009). However, in the case of genital inflammation, the number of virus that 
is transmitted may be increased (Haaland et al., 2009). 
 
Where HIV most commonly establishes primary infection in the female genital tract 
remains unknown, but HIV can infect vaginal, ectocervical, endocervical and uterine 
mucosa (Hladik and Hope, 2009, Howell et al., 1997). The multilayered epithelium of 
the vagina and ectocervix offers, when intact, a better mechanical protection against 
invading pathogens compared with the single-layer epithelium of the endocervix and 
endometrium (Pope and Haase, 2003). However, the larger surface area of the vagina 
and ectocervix provide greater access for HIV entry. Genital transmission of HIV/SIV 
has been reported in a woman born without a uterus (Kell et al., 1992) and in monkeys 
after hysterectomy (Miller et al., 1992). The potential benefit of blocking HIV exposure 
to the cervix by the use of a diaphragm was investigated in a large randomized 
controlled prevention clinical trial in African women (Padian et al., 2007). No 
significant reduction in HIV acquisition was observed in women using a diaphragm 
compared with the control group; however the sexual partners of the women using a 
diaphragm reported lower condom use than those in the control group. In summary, 
these reports suggest the vaginal mucosa as the initial transmission site for HIV. 
However, in the rhesus macaque model, foci of SIV RNA+ cells were identified in the 
endocervix and transformation zone (Li et al., 2009). 
 
Prior to the epithelium, the cervicovaginal secretions provide the first potential barrier 
for HIV. As mentioned before, the fluid contains antimicrobial cationic polypeptides 
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with anti-HIV activity. In addition, both virions and cell-bound HIV may be 
temporarily trapped by the cervical mucus (Maher et al., 2005). These two protective 
mechanisms may work synergistically, as the trapping may increase the possibility for 
soluble antiviral factors to attack the virus (Grivel et al., 2011).  
 
If HIV reaches the epithelium, the virus may cross via several mechanisms. Epithelial 
damage, due to genital infections or after “normal” sexual intercourse (Norvell et al., 
1984), is one possible entry mechanism. Furthermore, as described previously, the virus 
can be captured by intraepithelial LCs or the virus may penetrate the superficial layers 
of the epithelium and infect intraepithelial CD4+ T cells (Hladik et al., 2007). 
Moreover, virions may transcytose through single layer columnar epithelium or the 
basal layers of squamous epithelium (Hladik and Hope, 2009, Bomsel, 1997, Bobardt 
et al., 2007). HIV has been found to infect epithelial cells in vitro (Wu et al., 2003) and 
both endometrial and ectocervical epithelial cells may express CD4 and the chemokine-
coreceptors (Yeaman et al., 2003, Yeaman et al., 2004). As mentioned previously, 
susceptible HIV target cells in the genital tract mucosa are CD4+ T cells, DCs including 
LCs, and macrophages (Spira et al., 1996, Hu et al., 2000, Hladik et al., 2007). 
Observations in human tissue explant models (Hladik et al., 2007, Saba et al., 2010) 
and in rhesus macaques (Haase, 2010) suggest that CD4+ T cells are the initial targets 
in HIV infection. Especially ”resting” memory CD4+ T cells are the first cells to 
become infected, mainly due to the fact that they are more numerous than other 
potential target cells (Zhang et al., 1999, Zhang et al., 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 
Illustration showing some of the suggested routes for HIV transmission across squamous and columnar 
epithelium; after epithelial damage, by capture by intraepithelial Langerhans cells, transcytosis of 
virions and direct infection of epithelial cells.    
Copyright of Sam Hirbod, illustrator. 
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1.5.2 Viral and host factors modulating HIV susceptibility 
 
Several factors may influence the susceptibility of HIV infection in the FGT. A high 
viral load in the infected individual, which occurs during the early-stage of HIV 
infection, is associated with a higher risk of infection (Wawer et al., 2005). Sexually 
transmitted infections (STIs) in the non-infected subject increase the susceptibility, 
possibly by disrupting the epithelial barrier and/or by an increase in susceptible target 
cells (Laga et al., 1993, Plummer et al., 1991, Patterson et al., 1998). For example, 
following herpes simplex virus type 2 (HSV-2) infection, the number of potential HIV 
target cells was increased and persisted in the tissue despite of systemic antiviral 
treatment (Zhu et al., 2009). This may partly explain why HSV-2 treatment fails to 
reduce HIV acquisition. Moreover, concomitant HIV and STI infection increases viral 
load in genital secretions (Ghys et al., 1997, Cohen et al., 1997). In addition, factors in 
human semen may influence HIV susceptibility. A seminal peptide, named semen-
derived enhancer of virus infection (SEVI), enhances HIV infection in vitro through 
formation of amyloid fibrils that capture and focus virus onto target cells (Munch et al., 
2007). A genetic factor mediating decreased susceptibility against HIV is the mutation 
of the co-receptor CCR5 (CCR5 delta 32), which results in a non-functional receptor. 
Thus, a homozygous mutation results in a subsequent inability of R5 viruses to fuse 
with the target cell (Samson et al., 1996).  
 
 
 
1.5.3 Sex hormone levels and HIV susceptibility 
 
Several components of the mucosal immunity in the FGT vary with the changes in sex 
hormone levels during the menstrual cycle. Also exogenously applied sex hormones, 
such as the commonly used oral contraceptive pill, may influence the immune 
response. Wira el al have proposed a window of vulnerability for mucosal HIV 
acquisition 7-10 days following ovulation due to hormonal suppression on mucosal 
immunity (Wira and Fahey, 2008). Here, the menstrual cycle will be described briefly 
and some examples of hormonal regulation of the mucosal immunity will be discussed.    
 
During the first half of the menstrual cycle (the proliferative or preovulatory phase) 
estradiol (estrogen) levels increases gradually, peak a few days before ovulation and 
thereafter transiently declines. Following ovulation, the other sex hormone, 
progesterone, increases together with estradiol for 7-10 days (the secretory or 
postovulatory phase) after which both decline to initiate menstruation. These changes 
create an optimal environment for fertilization, but also affect the immune system in the 
FGT. In this thesis, menstrual cycle stage based on self-reporting is described as 
preovulatory or postovulatory stage (Papers I and IV) whereas stage determined by 
endometrial dating is described as proliferative or secretory stage (Papers II and III).  
 
At the level of the epithelium, progesterone implants are known to reduce vaginal 
epithelium thickness in rhesus macaques (Marx et al., 1996), but not in humans (Mauck 
et al., 1999). In women not using hormonal contraception, the number of vaginal 
epithelial cell layers was found to be the lowest in the secretory stage of the menstrual 
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cycle (Patton et al., 2000). Although statistically significant, the clinical significance of 
these changes was uncertain since they only consisted of one to two cell layers.  
 
The number and functional capacity of potential HIV target cells may vary with the 
menstrual cycle. In the endometrium, lymphoid aggregates consisting of a core of B 
cells surrounded by CD8+ T cells and macrophages, increased in size over the 
menstrual cycle (Yeaman et al., 1997). Furthermore, the cytotoxic activity of the CD8+ 
T cells in the endometrium and fallopian tubes was found to be suppressed during the 
secretory phase (Wira and Fahey, 2008). However, in an extensive study characterizing 
T cell subsets, natural killer cells (NK cells), macrophages and DCs at several locations 
in the lower FGT, no effect of menstrual cycle stage on cellular abundance or 
localization was seen (Pudney et al., 2005). Several soluble cationic polypeptides are 
influenced by sex hormones. In cervicovaginal lavage (CVL) samples, levels of SLPI 
and HNP 1-3 transiently decreased at the time of ovulation and thereafter increased 
during the secretory phase (Keller et al., 2007). In the uterus, Elafin mRNA expression 
peak during menstrual bleeding and the peptide is produced mainly by infiltrating 
neutrophils (King et al., 2003b). Our findings (Paper IV) show significantly lower 
levels of LL-37 and Trappin-2 in cervicovaginal secretions (CVS) from women 
currently using combined oral contraceptives (OC) as well as decreased Trappin-2 
mRNA expression in OC users.  
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1.6 HIV EXPOSED SERONEGATIVE INDIVIDUALS 
 
 
Some individuals remain uninfected despite repeated exposure to HIV and thus seem to 
be resistant to the infection. These HIV exposed seronegative (HESN) individuals have 
been found in a variety of cohorts including discordant couples (one partner HIV-
positive and the other HIV-negative), commercial sex workers, exposed health care 
workers and infants of HIV-infected mothers (Kulkarni et al., 2003). Several 
investigators have sought for the correlates of protection in these individuals and 
multiple mechanisms including systemic and mucosal cellular and humoral immune 
responses, innate immune responses, co-receptor mutations and genetic variations have 
been described. Here, a brief summary of some of these protective mechanisms will be 
presented. The majority of data has been obtained on uninfected individuals exposed by 
the sexual route. Of note, the already described mutation of the co-receptor CCR5 
(CCR5delta32) is the only mechanism that alone provide resistance to HIV infection 
(providing homozygous genotype and R5 strain infection). All other mechanisms 
described here most probably act together to provide an HIV-protective immune 
response.  
 
 
 
1.6.1 Innate immune responses in HESN 
 
Many innate immune factors may provide anti-HIV activity including the previously 
described cationic polypeptides as well as chemokines and cytokines. For example, 
three β-chemokines are natural ligands to the HIV co-receptor CCR5; Regulated upon 
activation normal T cell expressed and secreted (RANTES), macrophage inflammatory 
protein 1α (MIP-1α) and macrophage inflammatory protein 1β (MIP-1β), and are 
believed to reduce HIV-binding in a competitive manner. Elevated levels of RANTES 
have been found in the genital mucosa of HESN sex workers (Hirbod et al., 2006, Iqbal 
et al., 2005). MIP-1β and RANTES levels were elevated in the saliva of HESN MSM 
and the chemokine levels correlated with salivary HIV neutralization capacity 
(Hasselrot et al., 2010). Using a proteomics approach, the expression of 17 proteins in 
genital fluids was found to differ between HESN sex workers versus HIV-uninfected 
and HIV-infected sex workers in Kenya (Burgener et al., 2008). Most of the proteins 
that were up-regulated in the HESN individuals were anti-proteases. Further 
investigation is needed to explore if these anti-proteases protect against mucosal HIV 
acquisition, and in that case, whether they function similarly to other known anti-
proteases with anti-HIV activity (i.e. SLPI and Elafin).  
 
 
 
1.6.2 Adaptive immune responses in HESN 
 
HIV specific CD4+ T cells and CTLs as well as HIV neutralizing IgA antibodies have 
been found both systemically and in the FGT mucosa of HESN individuals (Miyazawa 
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et al., 2009). Proposed explanations for the induction of adaptive immune responses in 
HESN include: a) extraordinarily low levels of virus replication in the submucosal 
tissue without further dissemination to the lymphoid organs and/or, b) immune 
processing of viral fragments presented to the immune system without productive 
infection (Hirbod and Broliden, 2007). Furthermore, a continuous exposure to HIV is 
believed to be necessary to maintain an HIV-specific immunity both at the systemic 
and mucosal level in HESN subjects. Examples of adaptive immune responses in 
HESN women include HIV-specific CTLs in the systemic and mucosal compartment of 
sex workers (Kaul et al., 2000). Our group and others have found HIV-neutralizing IgA 
antibodies in saliva of HESN MSM (Hasselrot et al., 2009) and genital fluids of HESN 
sew workers (Devito et al., 2000, Hirbod et al., 2008). The neutralizing IgA antibodies 
may target antigens such as the receptors CCR5 and CD4 (Barassi et al., 2004), HLA-
molecules (Lopalco et al., 2000), carbohydrates on the HIV-envelope or epitopes 
displayed during the viral fusion (Ditzel et al., 1995). Other protective effects of soluble 
antibodies include opsonization ,which may result in activation of the complement 
system and complement-mediated lysis or uptake and destruction by phagocytes 
(Stoiber, 2009).      
 20 
2 AIM OF THESIS 
 
 
Toward the long-term goal of protecting women against STIs including HIV, the 
general aim of this thesis is to enhance understanding of HIV transmission events in the 
female genital tract. Specifically, the present work aims to: 
 
1. Ascertain and characterize the distribution of potential HIV target cells and 
cellular receptors in different regions (ectocervix, endometrium and endocervix) 
of the human female genital tract (Papers I-III respectively). 
 
2. Determine whether sexual behavior associated with a high-risk of acquiring 
HIV changes the distribution and abundance of HIV target cells (Paper I). 
 
3. Establish whether or not innate peptide levels are hormonally regulated (Paper 
IV). 
 
4. Evaluate the content of innate immune peptides with suggested anti-HIV 
activity in genital secretions and ectocervical tissue to seek a correlation, if any, 
between soluble levels and tissue expression at the individual level (Paper IV). 
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3 MATERIAL AND METHODS  
 
 
3.1 STUDY SUBJECTS AND SAMPLE COLLECTION 
 
Prior to start of all studies, ethical approvals were obtained.  
 
 
3.1.1 Paper I 
 
Cervical biopsies from the superior extocervix (avoiding the transformation zone) were 
collected from: 
 1) Eight African HIV-seronegative female sex workers that due to their occupation and 
reported lack of condom use were considered to be at high-risk for acquiring STIs 
including HIV.  
2) Ten African and Caucasian low-risk HIV-seronegative volunteers.  
The biopsies were immediately snap frozen in liquid nitrogen and stored at –80°C. All 
participating women were screened for STIs and answered a questionnaire regarding 
menstrual cycle stage, medical history and active medications including current use of 
contraceptives.  
 
 
 
3.1.2 Papers II and III 
 
Eight HIV-seronegative women with planned hysterectomy were recruited from the 
Department of Gynecology and Obstetrics at the Karolinska University Hospital 
Huddinge, Stockholm. Inclusion criteria were: HIV seronegative status, no clinical 
symptoms of STIs three months prior to the surgery and no use of hormonal therapy. 
All tissues were free from malignant and inflammatory diseases and pathology 
diagnosis was either leiomyomata or adenomyomata. Endometrial (n=8) and 
endocervical (n=6) tissue biopsies were collected by a gynecological pathology 
specialist. The biopsies were snap frozen in liquid nitrogen within 30 minutes of 
surgical removal and stored at –80°C. Menstrual cycle stage was determined by 
endometrial dating. 
 
 
 
3.1.3 Paper IV 
 
Twenty-five healthy HIV-seronegative female volunteers were enrolled from March 
2007 through June 2009 at the Department of Obstetrics and Gynecology, Karolinska 
University Hospital Huddinge, Sweden. Each woman underwent a pelvic examination 
followed by collection of a cervicovaginal secretion (CVS) sample and two biopsies 
taken from the superior portion of the ectocervix. Of the 25 women, 20 underwent a 
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second sampling of CVS and two ectocervical biopsies within nine to 26 months 
(median 23.8 months). The study also included samples from nine HIV-seronegative 
female sex workers from Nairobi, Kenya. At recruitment, these women had been active 
sex workers for a median of six years.  
 
Each CVS was collected using first a cotton-tipped swab that was rotated 360° in the 
ectocervical os and with a second swab that was used to collect secretions from the 
posterial vaginal fornix. Both swabs were transferred into a single vial containing 5 ml 
of phosphate-buffered saline (PBS) and transported on ice within 1h to the laboratory. 
To remove cellular debris the samples were centrifuged at 1500 rpm for 5 minutes, 
thereafter the supernatant was transferred to a new vial which was cryopreserved at      
–80°C.  
 
One of the collected ectocervical biopsies was immediately transferred to RNAlater 
buffer and stored at –80°C; the second biopsy was immediately snap frozen in liquid 
nitrogen and thereafter stored at –80°C.  
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3.2 METHODS 
 
 
3.2.1 In situ detection of cellular markers, receptors and innate immune 
factors by immunostaining – Papers I - IV 
 
Eight μm thick sections from cryopreserved ectocervical (papers I and IV), endometrial 
(paper II) and endocervical (paper III) biopsies were fixed in 2% formaldehyde, 
permeabilized, blocked for endogenous biotin and immunohistochemically stained as 
previously described (Lore and Andersson, 2004). Anti-human CD3, CD4, CD8, HLA-
DR, CD68, CD1a, CD11c, CD123, CD56, CD19, BDCA-2, Langerin, DC-SIGN, MR, 
IgD, CCR5 antibodies (papers I-III) as well as anti-human HNP 1-3, Trappin-2, SLPI, 
and LL-37 antibodies (paper IV) were used to detect the immune molecules of interest. 
Biotinylated secondary antibodies in combination with diaminobenzidine 
tetrahydochloride (DAB) (which creates a brown color) were used to visualize the 
positively stained markers of interest. Nuclear counterstaining was performed with 
hematoxylin. Negative control staining consisted of irrelevant anti-human IgG. Digital 
images were transferred from a DMR-X microscope (Leica, Wetzlar, Germany) into a 
computerized image analysis system, Quantimet, Q 550 IW (Leica Imaging Systems, 
Cambridge, UK). For one and double - fluorescent staining (papers I, II and III), the 
tissue sections were prepared as described above except that Alexa Fluor 488 
streptavidin or Alexa Fluor 594 labeled streptavidin were used to visualize the cells of 
interest.  
 
 
3.2.2 HNP 1-3, SLPI, Trappin-2 and LL-37 quantification – Paper IV 
 
Commercial enzyme-linked immunosorbent assay (ELISA) kits were used, according 
to the manufacturers protocols, to quantify the innate immune molecules of interest 
(additional CVS dilution in brackets): the α-defensins HNP-1-3 (1 : 100- 1 : 500), LL-
37 (1 : 5 - 1 : 10) Trappin-2 (1 : 50) and SLPI (1 : 100).  
 
 
3.2.3 Quantification of HNP 1-3, SLPI, Trappin-2 and LL-37 mRNA by 
real-time RT-PCR – Paper IV 
 
Detection of mRNA expression of interest was performed as previously described 
(Brismar Wendel et al., 2010). The RNAlater buffer stored biopsies were thawed and 
disrupted in lysis buffer with a mechanical rotor. RNA was extracted according to the 
manufacturers’ protocol (RNeasy kit) and converted in equal dilutions to cDNA in a 
single reverse transcriptase reaction using superscript II reverse transcriptase and 
random hexanucleotide primers. Amplification of ubiquitin C (UBC), Trappin-2, 
HNP1-3, SLPI and LL-37 was performed using the ABI PRISM 7500 sequence 
detection system and commercial FAMTM dye-labeled TaqMan MGB probes and 
primers. Each sample and control was run in duplicates. Ct values for target cDNA 
were normalized to UBC by using the 2-dCT method.  
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3.3 STATISTICAL ANALYSES 
 
 
3.3.1 Paper I 
 
Data were not normally distributed, thus all analyses were performed with non-
parametric tests. Intergroup variations of the markers of interest were analyzed by using 
the non-parametric Mann-Whitney U test. All calculations were performed with SPSS 
version 15.0 software (Chicago, IL, USA).  
 
 
3.3.2 Papers II and III 
 
No statistical analyses were performed in studies II and III due to the small number of 
study participants.  
 
 
3.3.3 Paper IV 
 
CVS samples with undetectable levels of innate factors were assigned a value at the 
assay cut-off. Tissue samples with undetectable mRNA levels of innate factors were 
assigned a value above Ct 40. Also the data in study IV were analyzed with the non-
parametric Mann-Whitney U test to compare two groups and the Spearman rank-order 
correlation test to assess correlations. All analyses were performed with the software 
GraphPad Prism 5.0 (GraphPad Software Inc, La Jolla, CA, USA).  
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3.4 TECHNICAL CONSIDERATIONS 
 
When collecting human mucosal samples several factors have to be taken into 
consideration. Furthermore, all laboratory methods have their pros and cons. Here, I 
discuss some aspects of these limitations that are relevant for this thesis. My focus will 
be on immunostaining since this is the major laboratory method used for this work.  
 
 
 
3.4.1 Collection of human mucosal samples 
 
As discussed previously, several factors may influence the immune milieu in the FGT 
including sex hormones and genital infections and, as such, constitute possible 
confounders. However, collection of a homogeneous study population with regard to 
menstrual cycle stage, use of hormonal contraception and presence of STIs is a 
complex task for several reasons. Firstly, hormonal contraceptive use is widespread, 
over 100 million women worldwide currently use the combined oral contraceptive pill 
(OC) (Hatcher, 2008). OC contain a combination of an estrogen and a progestin 
(progesterone) and inhibit fertilization by blocking ovulation and by decreasing cervical 
mucus permeability, whereas the inhibition of ovulation by contraceptives containing 
only progesterone is dose-dependent. Thus, study subjects using OC do not have intact 
ovulation and can therefore not be divided into pre- or postovulatory menstrual cycle 
stages. Secondly, many women have irregular menstrual cycles, usually due to 
differences in the length of the preovulatory phase of the cycle. Less than 15% of 
30 000 menstrual cycles reported by 650 women corresponded to a 28-day cycle 
(Hatcher, 2008). Thus, self-reporting of menstrual stage may be difficult and should 
ideally be supplemented with testing of serum estrogen and progesterone levels. 
Another option used in papers II and III is endometrial dating; however this requires 
endometrial biopsies. Screening for STIs is more straightforward, but includes the 
possible confounding factors that different laboratory methods may be used or 
diagnosis is determined clinically.  
 
 
 
3.4.2 Immunohistochemical and immunofluorescence staining 
 
Immunohistochemical staining enables the identification of immune markers at the 
cellular level within a tissue. In this thesis, both surface markers and secreted proteins 
have been assessed by this technique. The distribution of the markers of interest can be 
visualized, both in relation to other markers and to relevant anatomical structures (for 
example distance to the lumen). Immunofluorescence techniques facilitate multiple 
colors staining which can be used for phenotypical identification of for example CLR 
expression on a DC subset.   
 
In my opinion, the greatest advantage of immunostaining techniques is the visual 
identification of markers’ distribution at the cellular level. The other technique 
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commonly used to investigate immune cell populations in tissues; fluorescence-
activated cell sorting (FACS) (Quayle et al., 2007, Prakash et al., 2004), does not 
provide this information. However, with FACS the number of cells can be more 
accurately determined and the phenotype can be thoroughly investigated by multicolor 
FACS staining. A disadvantage of immunostaining is that the analysis is very time 
consuming and the percentages calculated may not be precise due to the semi-
quantitative analysis. But as long as one compares different groups that are analyzed 
with the same computerized analysis system one will be able to distinguish relevant 
differences. Furthermore, as no standard analysis system is agreed upon in the research 
community comparisons between studies are difficult.  
 
In the ectocervix, DC subsets and CLRs (paper I) as well as cationic polypeptides 
(paper IV) could be compartmentalized by tissue site; therefore the ectocervical 
biopsies were subdivided into epithelium and submucosa for the quantitative analysis. 
In an attempt to reflect the different staining patterns of cellular markers and secreted 
factors, the expression of cellular markers was determined as a percentage of positive 
staining out of total cell area, whereas expression of secreted innate immune factors 
was determined as a percentage of positive staining out of total tissue area. In the 
endocervical tissue (paper III), a distinct distribution pattern was seen for CD4+, CD8+ 
and CD11c+ cells with the majority of positive cells localized within or adjacent to the 
endocervical epithelium, whereas CD68+ cells were more evenly distributed in the 
endocervical tissue. Thus, the frequency of CD4+, CD8+ and CD11c+ expressing cells 
varied between different areas in the endocervical tissue, but was more uniform for 
CD68+ cells. However, we chose to quantify all markers in the same way so as to 
compare numbers of cells within different populations.  
 
A separate problem concerns sampling and the limited size of the tissue biopsies. 
Ideally, several tissue biopsies corresponding to the whole ectocervical region; i.e., a 
biopsy from the part of the ectocervix bordering the vagina, a biopsy closest to the 
transformation zone and several biopsies in between, should be assessed to investigate 
possible differences in abundance and distribution of cells (or other molecules) related 
to anatomical localization in the ectocervix. This is perhaps doable with hysterectomy 
specimens but, for ethical and clinical reasons, less feasible when taking biopsies 
during a gynecological examination.  
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4 RESULTS AND DISCUSSION 
 
 
4.1 PAPER I  
 
If HIV overcomes the physical and immunological barriers in the FGT mucosa, DC 
subsets in the epithelium or in the subjacent submucosa are among the first cells to 
encounter the virus. In paper I, we therefore characterized the distribution of DCs in the 
human ectocervix, determined their expression of HIV-binding CLRs and investigated 
whether the frequencies of immune cells and/or receptors differed between women in 
two groups: HIV-uninfected low-risk women and HIV-uninfected high-risk sex 
workers. At the time of biopsy collection, three women used hormonal contraception 
(one in the HIV high-risk group and two in the HIV low-risk group), and all but six 
women were in their postovulatory menstrual cycle stage (Errata in paper I where three 
participants using hormonal contraception are divided into postovulatory stage). 
Furthermore, all women were C trachomatis-, N gonorrhea-, syphilis- and candida- 
negative, but two of the subjects in the HIV high-risk group had clinical signs of 
bacterial vaginosis (BV). 
 
HLA-DR+, CD3+, CD4+, CD8+, CD11c+, CD1a+, CD123+ and CD68+, MR+, DC-
SIGN+ and Langerin+  cells were identified at the single cell level by 
immunohistochemistry and quantified by computerized image analysis. As MHC class 
II (HLA-DR) is expressed by all professional APCs to some extent, this marker was 
used to identify APCs including DCs. Cells expressing CD11c+ were defined as mDCs, 
whereas pDCs were identified by CD123+ expression. However, CD123 may also be 
expressed by other cell types including basophils (Agis et al., 1996, Janeway, 2005); 
therefore, a pDC-specific CLR; BDCA-2 (Dzionek et al., 2001) was included in papers 
II and III. LCs were identified by CD1a expression and macrophages defined as CD68+ 
cells.   
 
By two-color staining, we characterized the phenotype of the DCs. The different 
subsets were found to be differentially distributed in the ectocervical tissue. The 
CD123- CD68- CD11c+ mDCs were present both within the epithelium and subjacent in 
the submucosal compartment, whereas CD11c- CD123+ pDCs and CD1a- CD11c- 
CD123- CD68+ macrophages were only found in the submucosa. In all study 
individuals CD11c+ cells were more abundant than CD123+ cells. All CD1a+ LCs, 
which were located mainly in the epithelium, expressed CD11c. We further 
investigated CLR expression. Langerin was present on CD1a+ LCs and on rare CD1a- 
CD11c+ cells in the epithelium. In contrast, MR and DC-SIGN were exclusively 
expressed on cells in the submucosa: CD11c+ DC-SIGN+ mDCs, DC-SIGN+ MR+ 
CD68+ mDCs or macrophages and MR+CD68+ macrophages. The CD123+ cells did not 
express any of the investigated CLRs. Several of the ectocervices examined had 
submucosa that formed finger-like projections (papillae) into the squamous epithelium 
resulting in a reduced distance between the submucosa and the luminal surface. In 
several of the subjects, CD11c+, CD123+, MR+ and DC-SIGN+ cells were found within 
these papillae.  
 28 
Although the frequency of HLA-DR+, CD4+, and CD8+ cells was similar in the two 
study groups, the HIV high-risk women had a significantly higher expression of 
Langerin, MR and DC-SIGN as compared to the low-risk women (Figure 4). Although 
we could not perform intra-group statistical analysis, due to the small number of study 
subjects in each group, we did not note any obvious differences in the expression of the 
analyzed receptors in the two high-risk women with BV compared to the other women.   
 
  
  
 
 
 
 
 
 
 
Figure 4. 
 Langerin a), Mannose Receptor b) and DC-SIGN c) expression in the ectocervix of HIV low-risk and 
high-risk women. Y axis indicates the percentage of positive area as compared to the total cellular area. 
X axis indicates the study groups. Bar indicates the medians 
 
In conclusion, paper I describes the distribution of four cell populations expressing 
APC markers in the human ectocervix and further characterizes these cells with regard 
to their expression of HIV-binding CLRs. The findings contribute to previous reports 
on immune cell populations in the ectocervix (Geijtenbeek et al., 2000, Poppe et al., 
1998, Pudney et al., 2005). Whether the altered expression of CLRs in HIV high-risk 
women is caused by environmental factors such as exposure to HIV/other STIs or 
results from other factors such as genotype requires further investigation. Although the 
two study groups displayed similar numbers of APCs and T cells, the HIV high-risk 
women may have an up-regulated turn-over of their DCs as a result of mucosal 
disruptions from frequent sexual behaviors and possibly episodes of STIs. Tests of 
biopsies taken at several occasions would resolve this issue. Furthermore, a higher 
density of any CLR does not necessarily signify protection. As described previously, 
LCs may play dual roles in sexual transmission of HIV; immature LCs may protect 
against HIV acquisition via Langerin binding and degradation (de Witte et al., 2007b), 
whereas mature LCs may mediate HIV spread (Fahrbach et al., 2007). Thus, a high 
density of immature LCs (expressing high levels of Langerin) may contribute to 
protection against HIV in the context of low viral inoculum, whereas this protective 
mechanism may be lost if the LCs mature and down-regulate their Langerin expression 
(for example, during inflammatory conditions) or if Langerin binding is saturated due 
to a high viral load (de Jong et al., 2008, de Witte et al., 2007b). In support of this, we 
recently found up-regulated Langerin expression in the ectocervix of HESN sex 
workers as compared with lower risk individuals (Hirbod, unpublished data). In 
contrast, DC-SIGN interaction with HIV is considered to contribute to enhanced 
infectivity via cis- and trans-infection (Geijtenbeek et al., 2000, Burleigh et al., 2006). 
Furthermore, in addition to viral dose and maturation stage of the cell, the relative 
contribution of CLRs versus CD4 and CCR5 in HIV transmission events may vary in 
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the context of Langerin polymorphisms (Ward et al., 2006) and possibly in the presence 
of soluble HIV receptor ligands.  
 
 
 
4.2 PAPER II 
 
The lower FGT is often the main focus in research articles on sexual HIV transmission 
but initial HIV transmission events might also take place in the upper FGT (Wira and 
Fahey, 2008). In paper II, we therefore set out to investigate the distribution of potential 
HIV target cells and cellular receptors in the human endometrium. Previous work had 
showed that immune cell populations including CD4+ T cells, DCs and macrophages 
were present in the endometrium (Kamat and Isaacson, 1987, Laguens et al., 1990, 
Schulke et al., 2008, Starkey et al., 1991, Vassiliadou and Bulmer, 1996), and our aim 
was to further characterize these cells with regard to their expression of CCR5 and 
HIV-binding CLRs. Endometrial tissue biopsies were therefore collected from eight 
women undergoing hysterectomy due to benign bleeding disorders. Based on 
endometrial dating, two women had proliferative endometrium, three had secretory 
endometrium and three had inactive endometrium. In addition to the immune markers 
characterized in paper I, BDCA-2+ and CCR5+ cells were also identified at the single 
cell level by immunohistochemistry and quantified by computerized image analysis. 
The myometrium was excluded from the quantitative analysis.  
 
CD4+ cells were found within the columnar epithelium and in the endometrial stroma. 
CD4+ cells were either scattered in the stroma or aggregated within lymphoid 
formations. Endometrial lymphoid aggregates have been described previously, and they 
varied in size during the menstrual cycle (Kamat and Isaacson, 1987, Yeaman et al., 
1997). The phenotype of the cells was further characterized by two-color staining 
(Figure 5). The CD4+ cells represented T cells (defined as CD3+ CD4+ T cells) and DC 
subsets including mDCs (CD4+ CD11c+ cells) and LCs (CD4+ CD1a+ Langerin+ cells). 
Furthermore, both the intraepithelial and stromal CD4+ cells as well as CD3+ cells 
expressed the main co-receptor for HIV; CCR5. In addition to mDCs and LCs, CD68+ 
macrophages and CD123+ BDCA-2+ pDCs were found in the endometrium. Similarly 
to the findings in ectocervix, the APC subsets showed a compartmentalized distribution 
(Figure 6). Thus, the rare pDCs were localized solely in the endometrial stroma. In 
contrast, mDCs and macrophages were detected within the epithelium as well as 
scattered in the stroma and in lymphoid aggregates. LCs were localized mainly within 
the epithelium; however, Langerin expression was also detected in lymphoid 
aggregates. MR- and DC-SIGN-expressing cells were detected only in the stroma, 
albeit in close proximity to the uterine lumen, and represented both CD11c+ and CD68+ 
cells (Figure 6). 
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Figure 5.  
 a) Aggregate of CD4+ cells (stained brown) adjacent to glandular epithelium. Confocal images 
illustrating that CD4+ cells consisted of  b) CD3+ T cells, cells co-expressing CD4+ (red) and CD3+ 
(green) are yellow, c) CD11c+ myeloid DCs, double positive cells (yellow) co-expressing CD11c+ (red) 
and CD4+ cells (green) and d) CD1a+ Langerhans cells, CD4+ cells( red) and CD1a+ cells (green) 
double positive cells are yellow. e) Double-positive cells co-expressing (yellow) CCR5+ (red) and 
CD4+(green) were frequently observed within the luminal epithelium and underlying stroma. Scalebar 
100µm (a ) 25µm (b, d, e) 20 µm (c).   
 
 
 
 
 
 
 
 
 
 
Figure 6.  
Confocal images illustrating a) that some but not all stromal CD123+ cells (red) co-expressed (yellow) 
BDCA-2+(green). Both b) DC-SIGN+ (green) and c) MR+ expressing cells (green) were present in the 
endometrial stroma and were co-expressed (yellow) on b) CD11c+ (red) and c) CD68+ cells (red).  
 
To summarize paper II, we have described the presence of intraepithelial Langerin-, 
CD4- and CCR5-expressing cells in the human endometrium. Additional receptors with 
HIV-binding capacity such as MR and DC-SIGN were localized in the endometrial 
stroma. The role of all these potential HIV target cells as well as the occasional pDCs in 
HIV transmission events at this site remains to be established, for example in animal 
models or in human explant models. In theory, intraepithelial cells in single layer 
columnar epithelium are in direct contact with the lumen and could thus bind to HIV. 
Furthermore, as exposure of HIV gp120 can reduce the epithelial integrity through up-
regulation of inflammatory cytokines (Nazli et al., 2010), stromal cells may also be 
exposed to the virus. Owing the small size of the study group, the question whether 
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menstrual cycle stage influenced immune cell numbers was not addressed in paper II 
(nor in paper III). However, the distribution pattern of all investigated cell populations 
and receptors was similar in these women. Previously, the impact of sex hormones on 
endometrial cell populations was described as relatively stable numbers of CD4+ and 
CD8+ T cells throughout the menstrual cycle (Starkey et al., 1991, Vassiliadou and 
Bulmer, 1996), but an increase of macrophages, CD1a+ cells and CD56+ CD16- 
lymphocytes in the secretory stage (Kamat and Isaacson, 1987, Schulke et al., 2008, 
Starkey et al., 1991). CCR5 expression has been reported to be the highest during the 
proliferative stage (Yeaman et al., 2003), although another study showed no significant 
variations in CCR5 expression across the cycle (Mulayim et al., 2003). The conflicting 
results may result from different staining techniques or antibodies used and type of 
study subjects.  
 
 
 
4.3 PAPER III 
 
Owing to its anatomical localization and the fragile single layer epithelium, the 
endocervix has been considered a likely site for primary transmission of HIV. In 
support of this, endocervical foci of SIV RNA+ cells consisting primarily of CD4+ T 
cells were found in all infected monkeys in the rhesus macaque model, (n=9) (Li et al., 
2009). However, with respect to sexual transmission, the animal model differs from 
HIV in humans in several ways. A sexual act constitutes a mechanical trauma to the 
genital tissue, which may result in microabrasions (Norvell et al., 1984) as well as 
influx of leukocytes (Pandya and Cohen, 1985, Prakash et al., 2004). This contrasts 
with the atraumatic viral deposition in the animal model. Semen from an HIV-infected 
individual contains free virions and infected leukocytes, and both forms may establish 
HIV infection (Hladik and Hope, 2009), however to date virions are most commonly 
used in the animal model (Anderson, 2010). Thus, whether the human endocervix plays 
the same role in initial HIV transmission requires further studies. Ectopy has been 
associated with an increased risk of HIV (Moss et al., 1991), suggesting that the 
exposure of single-layered epithelium on the outside of cervix increases the risk of HIV 
acquisition. Furthermore, several immune cell populations including CD4+ T cells, DCs 
and macrophages are present in the human endocervix, particularly in the 
transformation zone (Pudney et al., 2005).  
 
In paper III, we characterized potential HIV target cells and receptors as well as 
described the distribution of immune effector cells in the human endocervix. Study 
participants were as in paper II, but endocervical biopsies were obtained from only six 
women. Based on endometrial dating, two participants were found in each group; 
proliferative, secretory and inactive endometrium. In addition to the immune markers 
used in papers I and II, CD8+, CD19+, CD56+ and IgD+ cells were identified at the 
single cell level by immunohistochemistry in paper III. Cells expressing CD8 were 
defined as CTLs, CD19+ cells were defined as B cells and CD56+ cells as a subset of 
NK cells.  
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In a distinct distribution pattern, most CD4+ cells, CD11c+ mDCs and CD8+ CTLs, but 
not the CD68+ macrophages , were located within or subjacent to the columnar 
epithelium (Figure 7). CD68+ cells were the most frequent of the investigated cells in 
the endocervix, yet CD1a+ LCs were the least abundant. LCs were located mainly 
within the epithelium, but were also found in the submucosa.  
 
 
 
 
 
 
 
 
 
 
Figure 7. 
Immunohistochemically stained sections of endocervical tissue (positive cells are stained brown) 
illustrating the distribution of CD4+, CD11c+, CD8+ and CD68+ cells.  
 
The phenotype of the cells was further characterized by two-color staining (Figure 8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.  
Confocal images of endocervical tissue sections illustrating a positive co-localization (yellow) of a) 
CD4+(green) and CCR5+ (red) cells and of b) CD11c+ (green) and CCR5+ (red) cells. c) Langerin+ 
(green) LCs were located mainly in the epithelium and co-expressed ( yellow) CD4+ (red). MR- and DC-
SIGN-expressing cells were present in the submucosa and consisted of both CD11c+ and CD68+ cells; d) 
DC-SIGN+ (red) and CD68+ (green) cells, double-positive cells ( yellow) e)MR+ (red) and CD11c+ 
(green) cells.   
 
Similarly to the endometrium, endocervical CD4+ cells consisted of CD3+ T cells as 
well as DC subsets including mDCs, LCs and pDCs. Furthermore, CCR5 expression 
was detected on CD11c+ and CD4+ cells. The HIV-binding CLRs were expressed by 
different APC subsets. Thus, Langerin was expressed by CD1a+ LCs, which also 
expressed CD4 and CD11c, but not CCR5. MR- and DC-SIGN-expressing cells were 
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exclusively present in the submucosa, albeit in close proximity to the lumen. MR and 
DC-SIGN were expressed by macrophages and mDCs, but not by LCs. In accordance 
with our previous findings in the ectocervix and endometrium, the rare CD123+ cells 
detected were present only in the submucosa. A subpopulation of the CD123+ cells 
(17%) co-expressed BDCA-2 and was thus defined as immature pDCs. The CD123+ 
cells did not express Langerin, MR or DC-SIGN. CD56+ NK cells were located both 
within the epithelium and in the submucosa, whereas CD19+ B cells and IgD+ cells 
were present in the submucosa alone.  
 
In conclusion, our findings in paper III suggest that several potential HIV target cells 
are present within or in close proximity to the endocervical epithelium under non-
inflammatory conditions. However, their role in HIV transmission events in vivo 
remains to be established. The distribution of HIV-binding CLRs in the endocervix 
followed a similar pattern as in the ectocervix and endometrium; thus, Langerin+ cells 
were localized mainly in the epithelium, whereas MR+ and DC-SIGN+ cells were 
present in the submucosa. This compartmentalization of MR- and DC-SIGN- 
expressing cells is also seen in human skin (Angel et al., 2007). Although CD1a+ cells 
have been described in the endocervices of rhesus macaques (Miller et al., 1992), and 
CD1a+ and Langerin+ cells have been detected in cytobrush-obtained human cervical 
samples (Prakash et al., 2004), ano-genital columnar epithelium has been proposed to 
lack LCs (Kawamura et al., 2005). Our finding of Langerin+ CD4+ CD11c+ CD1a+ LCs 
within and subjacent to the endocervical epithelium suggests that LCs indeed are 
present at this location. Based on the dual role of LCs in HIV acquisition, the function 
of the endocervical LCs may be either beneficial or detrimental depending on the 
circumstance. In addition, we observed occasional BDCA-2+ CD123+ pDCs in the 
endocervical submucosa. In contrast to human HSV-2 infection, where pDCs are 
proposed to play a role in the immune control of recurrent infection (Donaghy et al., 
2009) pDCs are part of the inflammatory innate immune response following SIV 
exposure that results in an influx of susceptible target cells in the endocervices of 
rhesus macaques (Li et al., 2009). The role of human pDCs during sexual HIV 
transmission remains to be established.  
 
 
 
4.4 PAPER IV 
 
In paper IV, we focused on the endocrine regulation of innate immune proteins with 
anti-HIV activity. We assessed several innate immune proteins in the ectocervix and in 
corresponding cervicovaginal fluids of both HIV-uninfected low-risk women and HIV- 
uninfected high-risk female sex workers and characterized their distribution in 
ectocervical tissue sections. We elucidated the association with hormonal contraception 
use and further examined if the soluble levels correlated with the tissue expression at 
the individual level. Entry characteristics of the participating women were determined 
by evaluation of the questionnaires and the results from STI screening. In Table 1, 
properties of the HIV low-risk women are summarized. As expected, the group of 
Kenyan female sex workers at high-risk of acquiring HIV differed with regard to 
several demographic variables (see Paper IV) as compared to the HIV low-risk women. 
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However, our aim when adding a HIV high-risk study group was to ascertain if the 
levels of innate peptides in genital fluids and ectocervical tissue correlated at the 
individual level in the context of different variables. Intergroup comparisons between 
HIV low-risk and HIV high-risk women were thus not performed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A discrepancy between soluble levels and tissue expression of innate immune peptides 
was observed in the low-risk women. In CVS, levels of HNP 1-3, SLPI and Trappin-2 
were plentiful, whereas LL-37 levels were lower. HNP 1-3 was the most abundant 
factor in CVS, whereas SLPI had the highest protein and mRNA expression in 
ectocervical tissue.  
 
To determine whether the innate immune peptides were hormonally regulated data 
from low-risk women were stratified according to current use of hormonal 
contraception. Significant associations were found between current use of OC and 
lower Trappin-2 mRNA expression as well as OC use and lower levels of soluble 
Trappin-2 and LL-37 (Figure 9). For progesterone IUD users the relationship was the 
opposite, i.e., levels of soluble LL-37 were significantly higher (Figure 9). The 
significant association for Trappin-2 and OC use persisted in a second sample taken 
within two years from sample one, which strengthens this observation. In a previous 
study performed on CVL samples from HIV-uninfected Kenyan sex workers, no 
correlation was found between hormonal contraceptive use and soluble levels of 
Trappin-2 and Elafin (Iqbal et al., 2009). Plausible explanations for this discrepancy are 
differing epidemiological factors between the study groups and disparate quantitative 
and sampling techniques. In addition to their anti-HIV activity in vitro (Ghosh et al., 
2010), elevated levels of Elafin and Trappin-2 have been associated with HIV non-
acquisition in an epidemiological study (Iqbal et al., 2009). Consequently, if the use of 
OC decreases the expression of Trappin-2, HIV susceptibility could increase. However, 
several factors may influence HIV susceptibility making the impact of lower Trappin-2 
levels alone difficult to interpret. Little is known about hormonal regulation of LL-37, 
but our findings indicate hormonal control of LL-37. In contrast, neither SLPI nor HNP 
1-3 differed in relation to hormonal contraception use. We recognize that the sample 
size of 25 women, of whom just over half were using hormonal contraception, is a 
limitation of the study. Nevertheless, significant differences were observed for certain 
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peptides. Most importantly, the present study will serve as a pilot for future evaluations 
of hormonal regulation of innate immune peptides and as a baseline for innate peptides 
levels in a low-risk setting.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. 
a) CVS levels of Trappin-2 b) Trappin-2 mRNA expression and c) soluble levels of LL-37 in women with 
(filled  circles) and without (boxes) current use of combined oral contraceptives. d) CVS levels of LL-37 
in women with (filled circles) and without (boxes) progesterone IUD. Lines depict median.  
 
 
We further investigated the distribution of SLPI+, HNP 1-3+, Trappin-2+ and LL-37+ 
cells in the ectocervix of HIV low-risk and high-risk woman by immunohistochemistry. 
The distribution pattern differed among the innate immune peptides; SLPI+, HNP 1-3+ 
and LL-37+ cells were located both in the submucosa and in the epithelium, whereas 
Trappin-2+ cells were observed mainly at the epithelial level. The compartmentalization 
of Trappin-2 expression to the ectocervical epithelium has been reported previously in 
the ectocervix as well as in other squamous epithelia (Pfundt et al., 1996). Our findings 
suggest that epithelial cells are the main producers of Trappin-2 in the ectocervix under 
non-inflammatory conditions. Two different staining patterns were observed for SLPI+- 
and HNP 1-3+-expressing cells. In the case of SLPI, the morphological appearance of 
positive cells in the epithelium differed from those in the submucosa. The cause may be 
different cellular sources of SLPI in these two compartments, which further 
investigation with double-staining techniques should clarify.  
 
At the individual level in both HIV low-risk and high-risk women, no correlation 
between soluble levels and tissue expression (including mRNA and protein expression) 
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of the innate immune peptides was observed. These findings thus suggest that CVS 
levels of the investigated peptides do not reflect their expression in the ectocervical 
tissue. As discussed previously in this thesis, genital fluids stem from various sources, 
and peptide levels measured in cervicovaginal fluid thus reflect the production by 
epithelial cells and immune cells at several locations in the FGT. With this in mind, the 
lack of association between individual levels of soluble peptide and tissue expression is 
comprehensible. Nevertheless, it emphasizes the importance of an evaluation at the 
tissue level in addition to cervicovaginal fluid, since we may miss important 
information about the mucosal immune response if only fluid samples are assessed. 
Moreover, the observed compartmentalization between ectocervical tissue and genital 
secretions may have implications for the evaluating of these factors’ impact on HIV 
susceptibility. Potentially, high levels of these molecules have a proinflammatory effect 
including target cell recruitment at the tissue level, whereas the same molecules could 
inhibit HIV entry when present in genital secretions.  
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5 CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
In conclusion, the work presented here shows the presence of several likely HIV target 
cells and receptors at three anatomical sites in the FGT. Although immune cell 
populations have been investigated previously in the FGT, our results in papers I – III 
add considerable information about the phenotypes of those cells and the expression of 
HIV-binding receptors including CLRs and CCR5. In the ectocervices of HIV high-risk 
women, the density of CLRs was significantly higher than in low-risk individuals. 
Further investigation is needed to understand the underlying mechanisms and function 
of this up-regulation and is currently on-going in our laboratory (Hirbod et al, 
unpublished data). As genital inflammation may increase HIV susceptibility by several 
mechanisms including recruitment of potential target cells, future studies must include 
women with inflammatory conditions. By increasing the number of study participants, 
potential changes in abundance and distribution of immune cell populations during the 
menstrual cycle could be statistically verified. Since the diverse collection techniques 
used to sample genital tract fluids often generate different quantitative results, possibly 
due to dilution effects or different amount of mucus collected, a standardization of 
sampling procedures would facilitate interpretation between studies. This also holds 
true for other mucosal samples including biopsies and cytobrush-derived fluids.  
 
A goal of HIV/AIDS research is the development of products designed to protect 
women against STIs including HIV. A microbicide is a topically applied (on the 
vaginal or rectal mucosa) compound designed to prevent the sexual transmission of 
HIV. In 2010, a randomized controlled trial of women in South Africa showed that 
sexual acquisition of HIV decreased in women using a vaginal gel of Tenefovir (an 
antiretroviral drug) as compared to placebo gel (Abdool Karim et al., 2010). However, 
when viral exposure is high, it is likely that more than one biomedical approach is 
needed to prevent primary HIV transmission (Shattock et al., 2011). Microbicide 
candidates could be based on hindering the interaction of HIV with its receptors 
including CCR5 (Kelly and Shattock, 2011) and CLRs (de Jong et al., 2010), thus 
knowledge of the presence and anatomical distribution of HIV-binding receptors and 
innate peptides in both low-risk and high-risk settings may be important when 
designing HIV-receptor blocking compounds. The work in this thesis was performed 
mainly on low-risk individuals, but our research group is currently investigating these 
molecules in women epidemiologically defined as HIV-resistant. Furthermore, in 
microbicide trials, it is important to monitor the elicited immune response, which may 
include production of chemokines, cytokines and/or innate immune peptides as well as 
potential changes in numbers of immune cells. Therefore, to assess the effect as well as 
safety of any such compound, we must have basic knowledge about the “normal” 
expression of these factors in both low- and high-risk individuals as a standard for 
comparison. Based on our findings in paper IV, which documented a 
compartmentalized distribution of innate immune peptides between ectocervical tissue 
and genital fluids, we suggest that mucosal immune responses should be monitored at 
the tissue level in addition to those in genital fluids. Moreover, menstrual cycle stage 
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and hormonal contraception use should be taken into account, since hormone levels 
may influence several aspects of mucosal immune responses.   
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6 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
 
Sommaren 1981 beskrevs de första fallen av förvärvat immunbristsyndrom (AIDS) i 
USA. Två år senare identifierade en fransk forskargrupp viruset som orsakat 
sjukdomen, humant immunbristvirus (HIV). Sedan starten av den globala HIV-
epidemin på 1980-talet, har över 25 miljoner människor dött av sjukdomens 
slutstadium AIDS. Över 33 miljoner människor lever med HIV idag, de flesta i södra 
Afrika. Trots intensiv forskning finns det ingen bot eller vaccin mot HIV, men sedan i 
mitten av 1990-talet kan man med effektiva mediciner bromsa AIDS-utveckling. 
Dessvärre har bara ungefär en tredjedel av alla människor i behov av bromsmedicin 
tillgång till detta.    
 
Oskyddat samlag är den vanligaste smittovägen för HIV, men viruset kan även smitta 
från en infekterad moder till hennes barn under graviditet, förlossning och amning eller 
via infekterat blod. Vid sexuell smitta måste viruset ta sig igenom slemhinnorna i anus, 
vagina eller munnen. Förutom vid oskyddat analsex, är den uppskattade risken för 
HIV-infektion vid oskyddat vaginalt och oralt samlag inte större än 1:200. Orsaken till 
detta är sannolikt att slemhinnans naturliga immunförsvar hindrar HIV-smitta vid de 
flesta oskyddade samlag. Naturligt förekommande skydd mot HIV i kvinnliga genitalia 
utgörs av både fysiska och immunologiska barriärer. Exempel på fysiska barriärer är 
den tjockflytande vätskan (sekretet) som täcker slemhinnan och en intakt yttre del      
(epitel) på slemhinnan. Sekretet innehåller dessutom flera olika lösliga molekyler som 
verkar skyddande mot HIV (anti-HIV-effekt). Om viruset trots allt tar sig igenom 
skyddsbarriärerna så kan det binda till och infektera flera olika typer av celler (HIV-
målceller); CD4+ T lymfocyter, dendritiska celler (DCs) och makrofager. För att HIV 
ska infektera en målcell måste den ta sig in i  cellen genom att först binda till ett 
ytprotein på målcellen, CD4, och därefter till ytterligare ett protein (de så kallade co-
receptorerna) CCR5 eller CXCR4. Förutom via CD4 och CCR5/CXCR4 så kan DC 
och makrofager även binda HIV med hjälp av andra ytmolekyler; till exempel via C-
type lectin receptorer (CLRs). Tre stycken olika CLRs; Langerin, DC-SIGN och 
Mannose Receptor (MR), kan binda till HIV men resultatet av denna binding varierar. 
Om DC-SIGN binder till viruset ökar smittsamheten eftersom detta resulterar i att även 
CD4+ T cells blir infekterade. Langerin däremot kan i vissa fall skydda mot HIV-
smitta, då viruset efter Langerin bindning förstörs inuti cellen. Langerin, DC-SIGN och 
MR finns uttryckt på olika typer av DCs och makrofager. Langerin finns endast på en 
DC subtyp som kallas Langerhanska celler (LCs)  som framförallt är lokaliserade i 
slemhinnans epitel. MR och DC-SIGN finns på makrofager och DCs. De celler som 
uttrycker MR och DC-SIGN är belägna djupare i slemhinnan nedanför epitelet i den så 
kallade submukosan.  
 
 I denna avhandling har vi undersökt distributionen av potentiella målceller för HIV på 
tre ställen i kvinnliga genitalia; ektocervix (yttre delen av livmodertappen), endocervix 
(inre delen av livmodertappen) och endometriet (livmoderns slemhinna) samt 
förekomsten av lösliga faktorer med anti-HIV-effekt i genitalt sekret och på 
vävnadsnivå i ektocervix. Resultaten från studie I-III visar att flera potentiella målceller 
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för HIV fanns i ektocervix, endocervix och endometriet. Till exempel fann vi både 
CD4+ T celler och Langerin+ LC i det enkelradiga epitelet som är ytterst på slemhinnan 
i endocervix och endometriet. Dessa målceller är i princip i direkt kontakt med utsidan 
på slemhinnan och skulle därför kunna binda till virus i HIV-infekterad sperma. 
Enkelradigt epitel är därtill mer känsligt för HIV-smitta jämfört med flerradigt epitel 
eftersom det lättare går sönder. Vidare bekräftar våra resultat tidigare fynd att de olika 
CLRs uttrycks av olika typer av DCs och makrofager. På samtliga undersökta 
lokalisationer fanns Langerin på LCs, medan MR och DC-SIGN fanns på makrofager 
och DC i submukosan. Vidare såg vi att HIV-negativa prostituerade kvinnor hade mer 
Langerin, MR och DC-SIGN i ektocervix jämfört med HIV-negativa friska kvinnor. 
Huruvida den högre produktionen av CLR ledde till ett skydd mot sexuell HIV-smitta 
går inte att fastställa av vår studie, men vår grupp undersöker detta vidare hos bland 
annat prostituerade som trots att de upprepade gånger exponerats för HIV inte blivit 
HIV-infekterade (så kallade exponerade oinfekterade individer). I studie IV 
observerade vi att förekomsten av faktorer med anti-HIV-effekt skiljde sig mellan 
genitalt sekret och i ektocervikal vävnad. Vi föreslår därför att man bör undersöka både 
sekret och vävnad vid studier av slemhinnans immunförsvar, för om man bara 
undersöker det i en lokal så är risken att man missar viktig information. Vidare såg vi 
att användning av p-piller minskade nivåerna av några av de undersökta faktorerna. Då 
dessa faktorer verkar skyddande mot HIV skulle p-pilleranvändning därmed eventuellt 
kunna öka risken för sexuell HIV-smitta. Viktigt att påpeka i sammanhanget är att ett 
flertal faktorer påverkar risken för sexuell HIV-smitta och därför är det svårt att uttala 
sig precist om betydelsen av enskilda faktorer.  
 
Sammanfattningsvis önskar jag att studierna i denna avhandling ska bidra till en ökad 
förståelse för mekanismerna bakom HIV-infektion i kvinnliga genitalia samt att de kan 
vara betydelsefulla när man ska designa skyddande läkemedel mot sexuell HIV-smitta.  
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